181 related articles for article (PubMed ID: 16301630)
1. The inhibition of autoreactive T cell functions by a peptide based on the CDR1 of an anti-DNA autoantibody is via TGF-beta-mediated suppression of LFA-1 and CD44 expression and function.
Sela U; Mauermann N; Hershkoviz R; Zinger H; Dayan M; Cahalon L; Liu JP; Mozes E; Lider O
J Immunol; 2005 Dec; 175(11):7255-63. PubMed ID: 16301630
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of stromal cell-derived factor-1alpha-induced T cell chemotaxis by a peptide based on the complementarity-determining region 1 of an anti-DNA autoantibody via up-regulation of TGF-beta secretion.
Sela U; Hershkoviz R; Cahalon L; Lider O; Mozes E
J Immunol; 2005 Jan; 174(1):302-9. PubMed ID: 15611253
[TBL] [Abstract][Full Text] [Related]
3. The negative regulators Foxj1 and Foxo3a are up-regulated by a peptide that inhibits systemic lupus erythematosus-associated T cell responses.
Sela U; Dayan M; Hershkoviz R; Cahalon L; Lider O; Mozes E
Eur J Immunol; 2006 Nov; 36(11):2971-80. PubMed ID: 17051618
[TBL] [Abstract][Full Text] [Related]
4. A peptide based on the complementarity-determining region 1 of an autoantibody ameliorates lupus by up-regulating CD4+CD25+ cells and TGF-beta.
Sharabi A; Zinger H; Zborowsky M; Sthoeger ZM; Mozes E
Proc Natl Acad Sci U S A; 2006 Jun; 103(23):8810-5. PubMed ID: 16735466
[TBL] [Abstract][Full Text] [Related]
5. A peptide that ameliorates lupus up-regulates the diminished expression of early growth response factors 2 and 3.
Sela U; Dayan M; Hershkoviz R; Lider O; Mozes E
J Immunol; 2008 Feb; 180(3):1584-91. PubMed ID: 18209054
[TBL] [Abstract][Full Text] [Related]
6. The role of apoptosis in the ameliorating effects of a CDR1-based peptide on lupus manifestations in a mouse model.
Sharabi A; Luger D; Ben-David H; Dayan M; Zinger H; Mozes E
J Immunol; 2007 Oct; 179(8):4979-87. PubMed ID: 17911582
[TBL] [Abstract][Full Text] [Related]
7. The suppression of murine lupus by a tolerogenic peptide involves foxp3-expressing CD8 cells that are required for the optimal induction and function of foxp3-expressing CD4 cells.
Sharabi A; Mozes E
J Immunol; 2008 Sep; 181(5):3243-51. PubMed ID: 18713995
[TBL] [Abstract][Full Text] [Related]
8. Clinical amelioration of murine lupus by a peptide based on the complementarity determining region-1 of an autoantibody and by cyclophosphamide: similarities and differences in the mechanisms of action.
Sharabi A; Azulai H; Sthoeger ZM; Mozes E
Immunology; 2007 Jun; 121(2):248-57. PubMed ID: 17346282
[TBL] [Abstract][Full Text] [Related]
9. A peptide based on the complementarity determining region 1 of a human monoclonal autoantibody ameliorates spontaneous and induced lupus manifestations in correlation with cytokine immunomodulation.
Luger D; Dayan M; Zinger H; Liu JP; Mozes E
J Clin Immunol; 2004 Nov; 24(6):579-90. PubMed ID: 15622442
[TBL] [Abstract][Full Text] [Related]
10. Modulation of autoreactive responses of peripheral blood lymphocytes of patients with systemic lupus erythematosus by peptides based on human and murine anti-DNA autoantibodies.
Sthoeger ZM; Dayan M; Tcherniack A; Green L; Toledo S; Segal R; Elkayam O; Mozes E
Clin Exp Immunol; 2003 Feb; 131(2):385-92. PubMed ID: 12562403
[TBL] [Abstract][Full Text] [Related]
11. The mechanism by which a peptide based on complementarity-determining region-1 of a pathogenic anti-DNA auto-Ab ameliorates experimental systemic lupus erythematosus.
Eilat E; Dayan M; Zinger H; Mozes E
Proc Natl Acad Sci U S A; 2001 Jan; 98(3):1148-53. PubMed ID: 11158609
[TBL] [Abstract][Full Text] [Related]
12. The role of dendritic cells in the mechanism of action of a peptide that ameliorates lupus in murine models.
Sela U; Sharabi A; Dayan M; Hershkoviz R; Mozes E
Immunology; 2009 Sep; 128(1 Suppl):e395-405. PubMed ID: 19040426
[TBL] [Abstract][Full Text] [Related]
13. Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): immunomodulation of gene expression.
Sthoeger ZM; Sharabi A; Molad Y; Asher I; Zinger H; Dayan M; Mozes E
J Autoimmun; 2009 Aug; 33(1):77-82. PubMed ID: 19346102
[TBL] [Abstract][Full Text] [Related]
14. A peptide based on the CDR3 of an anti-DNA antibody of experimental SLE origin is also a dominant T-cell epitope in (NZBXNZW)F1 lupus-prone mice.
Brosh N; Dayan M; Fridkin M; Mozes E
Immunol Lett; 2000 Apr; 72(1):61-8. PubMed ID: 10789683
[TBL] [Abstract][Full Text] [Related]
15. Amelioration of SLE-like manifestations in (NZBxNZW)F1 mice following treatment with a peptide based on the complementarity determining region 1 of an autoantibody is associated with a down-regulation of apoptosis and of the pro-apoptotic factor JNK kinase.
Rapoport MJ; Sharabi A; Aharoni D; Bloch O; Zinger H; Dayan M; Mozes E
Clin Immunol; 2005 Dec; 117(3):262-70. PubMed ID: 16257268
[TBL] [Abstract][Full Text] [Related]
16. The tolerogenic peptide hCDR1 downregulates pathogenic cytokines and apoptosis and upregulates immunosuppressive molecules and regulatory T cells in peripheral blood mononuclear cells of lupus patients.
Sthoeger ZM; Sharabi A; Dayan M; Zinger H; Asher I; Sela U; Mozes E
Hum Immunol; 2009 Mar; 70(3):139-45. PubMed ID: 19280712
[TBL] [Abstract][Full Text] [Related]
17. A peptide based on the CDR1 of a pathogenic anti-DNA antibody is more efficient than its analogs in inhibiting autoreactive T cells.
Eilat E; Fridkin M; Mozes E
Immunobiology; 2000 Nov; 202(4):383-93. PubMed ID: 11131154
[TBL] [Abstract][Full Text] [Related]
18. Characterization and role in experimental systemic lupus erythematosus of T-cell lines specific to peptides based on complementarity-determining region-1 and complementarity-determining region-3 of a pathogenic anti-DNA monoclonal antibody.
Brosh N; Eilat E; Zinger H; Mozes E
Immunology; 2000 Feb; 99(2):257-65. PubMed ID: 10692045
[TBL] [Abstract][Full Text] [Related]
19. A peptide based on an anti-DNA autoantibody downregulates matrix metalloproteinases in murine models of lupus.
Faber-Elmann A; Eilat E; Zinger H; Mozes E
Clin Immunol; 2002 Nov; 105(2):223-32. PubMed ID: 12482397
[TBL] [Abstract][Full Text] [Related]
20. Amelioration of brain pathology and behavioral dysfunction in mice with lupus following treatment with a tolerogenic peptide.
Lapter S; Marom A; Meshorer A; Elmann A; Sharabi A; Vadai E; Neufeld A; Sztainberg Y; Gil S; Getselter D; Chen A; Mozes E
Arthritis Rheum; 2009 Dec; 60(12):3744-54. PubMed ID: 19950283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
